Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,102 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Familial Hypoalphalipoproteinemia
Interventions: CER-001, Placebo; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain
Interventions: Intrathecal morphine injection, EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 5
States / cities: Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more

Conditions: Aging
Interventions: Placebo, Testosterone; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Galveston, Texas • Texas City, Texas

Conditions: Tennis Elbow, Lateral Epicondylitis
Interventions: Placebo Injection, Physical Therapy, Corticosteroid Injections, Prolotherapy; Drug · Behavioral
Lead sponsor: Christine M. Kleinert Institute for Hand and Microsurgery; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Osteoarthritis of the Knee
Interventions: FX006, Placebo, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: Tislelizumab, Ociperlimab, Pembrolizumab, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more

Conditions: Osteoarthritis, Osteo Arthritis Knee, Osteo Arthritis Shoulders, Osteoarthritis of Multiple Joints, Osteoarthritis, Hip, Osteoarthritis - Ankle/Foot
Interventions: Tissue Stromal Vascular Fraction (tSVF) Arm 1, PRP Concentrate Arm 1, Tissue Stromal Vascular Fraction (tSVF) Arm 2, PRP Concentrate Arm 2, Cellular Stromal Vascular Fraction (cSVF) Arm 2, Cellular Stromal Vascular Fraction (cSVF) Arm 3, Sterile Normal Saline (IV Solution); Procedure · Biological · Drug
Lead sponsor: Healeon Medical Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Valencia, California • Stevensville, Montana

Conditions: Osteoarthritis (OA) of the Knee
Interventions: Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative, Major Abdominal Surgery
Interventions: TAP block, Epidural analgesia, EXPAREL, Bupivacaine; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Pain, Postoperative
Interventions: Liposomal Injection Bupivacaine (Exparel), Standard bupivicaine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Pleural Effusion
Interventions: normal saline, TNK (Tenecteplase); Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Chronic Kidney Disease
Interventions: L-Arginine, Placebo; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 35 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Newark, Delaware • Dallas, Texas

Conditions: COVID-19
Interventions: BBV152; Biological
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Tempe, Arizona • Miami, Florida • Miami Lakes, Florida + 6 more

Conditions: Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Interventions: Zilretta Injectable Product or Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Mosquito-Borne Infectious Diseases
Interventions: AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cocaine Use Disorder
Interventions: Exenatide, Placebo; Drug
Lead sponsor: Christopher D. Verrico; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Normal Physiology
Interventions: Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Blood Loss Anemia, Fracture
Interventions: Iron-Dextran Complex Injection [InFed], Saline Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hidradenitis Suppurativa
Interventions: 23.4% Hypertonic saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postsurgical Pain, Analgesia, Prostatectomy
Interventions: EXPAREL 20 mL, EXPAREL 40 mL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Pain
Interventions: Obturator Nerve Block, Ropivacaine, Placebo Saline; Procedure · Drug
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions: Standard number of injection sites, Reduced number of injection sites; Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Shigella
Interventions: SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

Effect of Steroid Injections in a Knee With Osteoarthritis

Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

Exparel vs. Standard Bupivicaine for Abdominoplasty

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

Corticosteroid Meniscectomy Randomized Trial

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Platelet Rich Plasma Injections In Young And Old Human Subjects

Exenatide For Reducing the Reinforcing Effects of Cocaine

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma

Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa

TAP-patients With Robotic Assisted Lap Prostatectomy

Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine